Is Cerus Corporation (CERS) overvalued? · rev $201.3M
Cerus Corporation (CERS) is a medical devices company listed on US.
This page asks whether Cerus Corporation (CERS) looks expensive on cached numbers — not a short thesis.
Latest reported CERS revenue for 2024-12-31 was $201.3M. Net income was -$21.0M. Revenue was up 7.8% from 2023-12-31 to 2024-12-31. CERS currently screens at market cap $294.4M.
CERS currently screens at market cap $294.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CERS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CERS stock page for the full model, not this heading.
Not investment advice.